Biventricular assist devices in children with severe heart failure serves as bridge to transplant
In a recent study, nine pediatric patients with severe
heart failure were successfully kept alive for an average of 35 days with miniaturized
heart assist pumps while awaiting a heart transplant, according to a report in
the Cardiovascular Surgery Supplement of Circulation: Journal of the American
Heart Association.
"It is not unusual for a child at the top of the transplant
candidate list to wait several months before an organ becomes available," said
Sanjiv K. Gandhi, M.D., lead author of the study, cardiothoracic surgeon, and
Surgical Director of the Heart Failure program at Saint Louis Children's Hospital
in Missouri.
Researchers implanted biventricular assist devices, known
as BiVADs, in seven girls and two boys ranging in age from 12 days to 17 years.
All had severe heart failure due to cardiomyopathy or complex congenital heart
defects and weighed less than 40 kilograms (88 pounds). One child died from kidney
failure before receiving a heart transplant. After 19 months of follow up, the
other eight were alive with new hearts.
Children who need heart transplants and are very ill
can be placed on external circulatory support machines, but their long-term use
is associated with significant risks. Patients also must be immobilized, which
impairs physical rehabilitation efforts.
The ventricular assist devices allow for physical rehabilitation
that improves the patient's overall condition and likelihood of successful transplantation,
researchers said. In this study, complications such as postoperative bleeding
and blood clots blocking a blood vessel occurred infrequently, but there was a
high incidence of blood clotting in the pumps.
Small heart pump devices have been available in Europe
for many years, but they are not approved for use in North America. However, the
miniaturized Berlin Heart EXCORR ventricular assist device recently became available
in North America on a compassionate use basis, meaning patients can be approved
for the pumps if they have no other treatment options.
The data emphasize the importance of continued development
and refinement of mechanical ventricular assist devices in the pediatric population,
researchers said.
|